Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
Date:8/31/2013

or symptoms of blood loss (e.g., a drop in hemoglobin and/or hematocrit or hypotension). Discontinue PRADAXA in patients with active pathological bleeding.
  • Risk factors for bleeding include concomitant use of medications that increase the risk of bleeding (e.g., anti-platelet agents, heparin, fibrinolytic therapy, and chronic use of NSAIDs). PRADAXA's anticoagulant activity and half-life are increased in patients with renal impairment.
  • A specific reversal agent for dabigatran is not available. Hemodialysis can remove dabigatran; however clinical experience for hemodialysis as a treatment for bleeding is limited. Activated prothrombin complex concentrates, recombinant Factor VIIa, or concentrates of factors II, IX or X may be considered but their use has not been evaluated. Protamine sulfate and vitamin K are not expected to affect dabigatran anticoagulant activity. Consider administration of platelet concentrates where thrombocytopenia is present or long-acting antiplatelet drugs have been used.
  • Thromboembolic and Bleeding Events in Patients with Prosthetic Heart Valves
    The safety and efficacy of PRADAXA in patients with bileaflet mechanical prosthetic heart valves (recently implanted or implanted more than 3 months prior to enrollment) was evaluated in the phase 2 RE-ALIGN trial. RE-ALIGN was terminated early because of significantly more thromboembolic events (valve thrombosis, stroke, transient ischemic attack, and myocardial infarction) and an excess of major bleeding (predominantly post-operative pericardial effusions requiring intervention for hemodynamic compromise) for PRADAXA vs warfarin. Therefore, the use of PRADAXA is contraindicated in patients with mechanical prosthetic valves.

    Use of PRADAXA for the prophylaxis of thromboembolic events in patients with AFib in the setting of other forms of valvular heart disease, including bioprosthetic heart valve, has not been studied and is not recommended.

    Ef
    '/>"/>

    SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
    2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
    3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
    4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
    5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
    6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
    7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
    8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
    9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
    10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
    11. Boehringer Ingelheim Announces Equine Research Awards
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2014)... -- Apex Medical Corporation (Apex, TWSE: 4106), a leading player ... that it is appealing the judgment of the Regional Court ... that found the headgear of certain mask models ... invalidity challenges against various ResMed patents in major countries. Apex ... junk patents. ResMed filed the lawsuit with ...
    (Date:7/29/2014)... 29, 2014  Ambit Biosciences (Nasdaq: AMBI ), ... drugs targeting unmet needs in oncology, autoimmune and inflammatory ... results after closing of the NASDAQ Global Market on ... call hosted by Michael Martino , president and ... place on the same day at 5:00 pm EDT ...
    (Date:7/29/2014)... , July 29, 2014  The BioFusionary ... on developing a proprietary electromagnetic induction platform with ... into an agreement under which TBC will merge ... Limited (COT) in an all-stock transaction. ... initially trade on the Australian Stock Exchange under ...
    Breaking Medicine Technology:Apex Continues Fighting Against Patents to Free Up Competition 2Ambit Biosciences To Announce Second Quarter 2014 Financial Results 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 2The BioFusionary Corporation, Inc. Announces Intent To Complete Reverse Takeover Of Australia-Based Continuation Investments Limited 3
    ... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
    ... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
    Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
    (Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
    (Date:7/29/2014)... 29, 2014 “Our years of ... homeowners fail to insulate their homes properly simply ... of preventing heat transfer and conduction,” Clean Crawls ... they’ve recently released an article explaining exactly how ... their energy bills. , To contact Clean Crawls ...
    (Date:7/29/2014)... “Approximately 18% of our population suffers from allergies, ... Western Washington Medical Group says in their recently ... from allergies to seek medical attention. , “Billions of ... in the United States,” they continue. “Many people have ... themselves, rather than seeking the appropriate treatment.” , Fortunately, ...
    (Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign ... absorb embarrassing odors in the office. PoofPad is a discrete ... a desk drawer. This compact packaging is designed for ease ... on the pad and poof away! , “We’ve all been ... someone appears out of nowhere. It’s embarrassing and unpleasant for ...
    (Date:7/29/2014)... 29, 2014 Riverdale Urgent Care is ... do. Through their presence at local events, partnerships and ... more than just a medical service for the Riverdale ... money in support of Riverdale RiverFest and South Riverdale ... that features local musicians and entertainers, arts and crafts, ...
    Breaking Medicine News(10 mins):Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2Health News:What’s The Point of Insulation? Clean Crawls Explains The Dangers of Heat Transfer in Recently Released Article 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 2Health News:Allergy Sufferers are Urged to Seek Medical Help in Recent Article by Western Washington Medical Group 3Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 2Health News:Riverdale Urgent Care of the Bronx, NY Puts a Face Back on Medicine 3
    ... Regions Hospital,this week opens a new 16-bed inpatient ... the region -- with an innovative way of caring ... schedule,providing improved continuity and a better experience for patients., ... provide care for,patients once they arrive in the emergency ...
    ... Late-Stage and Marketed ... ... England, February 18 /PRNewswire/,-- EUSA Pharma Inc (,EUSA,), a transatlantic ... today,announced that it has out-licensed the exclusive world-wide rights to ...
    ... Cancer Society study of twelve types of cancer among ... were significantly more likely to present with advanced stage ... which appears in the March issue of The Lancet ... investigate insurance status and stage of diagnosis for a ...
    ... known to impair the cognitive health of people, but ... learning and memory problems. A new National Institutes ... increased levels of a stress hormone produced by the ... the region of the brain responsible for learning and ...
    ... District Hospital, Dar es Salaam, Tanzania, WASHINGTON, Feb. ... President, First Lady, my dear wife -- Mr.,President, welcome again ... you so much, again, for PEPFAR, the President,s,Emergency Plan for ... -- these two buildings, a,facility we just visited, and again, ...
    ... Wing, professor of psychiatry and human behavior at The Warren ... Weight Control & Diabetes Research Center at The Miriam Hospital, ... dieters who lose weight and keep the pounds off, have ... , Using new research findings, Wing will make her case ...
    Cached Medicine News:Health News:Regions Hospital to Open New Inpatient Behavioral Health Unit 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 2Health News:EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties 3Health News:Major study links insurance status to advanced stage in multiple cancers 2Health News:Stress hormone impacts memory, learning in diabetic rodents 2Health News:Remarks By President Bush and President Kikwete of Tanzania at Roundtable on Pepfar 2Health News:Large changes needed to address global obesity epidemic 2
    1.7% Tryptone, 0.3% Soytone, 0.5% Sodium Chloride, 0.25% Dextrose, 0.25% Potassium Phosphate....
    Penicillin G (1 x 10 4 units/mL and Streptomycin (10mg/mL) Solution. 100X Concentrate....
    Penicillin-Streptomycin-Glutamine (100X) liquid...
    Contains 10,000 units of penicillin (base), 10,000 g of streptomycin (base), and 25 g of amphotericin B/ml utilizing penicillin G (sodium salt), streptomycin sulfate, and amphotericin B as Fungizone ...
    Medicine Products: